Wang J, Li R, Huang C, Hong C, Li Q, Zeng L
Liver Res. 2025; 6(3):175-180.
PMID: 39958197
PMC: 11791789.
DOI: 10.1016/j.livres.2022.05.004.
Simunic M, McGraw K, Pavletic S, Rashidi A
Semin Hematol. 2024; 61(6):442-448.
PMID: 39551677
PMC: 11646173.
DOI: 10.1053/j.seminhematol.2024.10.006.
Nie F, Guo J, Pan J, Guo Z, Wang C, Yan J
Clin Transl Oncol. 2024; 27(2):790-799.
PMID: 39046682
DOI: 10.1007/s12094-024-03615-0.
Kustrimovic N, Bilato G, Mortara L, Baci D
Int J Mol Sci. 2024; 25(3).
PMID: 38339010
PMC: 10855347.
DOI: 10.3390/ijms25031732.
Zhang M, Liu J, Xia Q
Exp Hematol Oncol. 2023; 12(1):84.
PMID: 37770953
PMC: 10537950.
DOI: 10.1186/s40164-023-00442-x.
Association of Antibiotic Receipt With Survival Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma Receiving Chemotherapy.
Fulop D, Zylberberg H, Wu Y, Aronson A, Labiner A, Wisnivesky J
JAMA Netw Open. 2023; 6(3):e234254.
PMID: 36951863
PMC: 10037151.
DOI: 10.1001/jamanetworkopen.2023.4254.
A systematic review and meta-analysis evaluating the impact of antibiotic use on the clinical outcomes of cancer patients treated with immune checkpoint inhibitors.
Crespin A, Le Bescop C, de Gunzburg J, Vitry F, Zalcman G, Cervesi J
Front Oncol. 2023; 13:1075593.
PMID: 36937417
PMC: 10019357.
DOI: 10.3389/fonc.2023.1075593.
Do proton pump inhibitors alter the response to immune checkpoint inhibitors in cancer patients? A meta-analysis.
Lopes S, Pabst L, Dory A, Klotz M, Gourieux B, Michel B
Front Immunol. 2023; 14:1070076.
PMID: 36776847
PMC: 9910608.
DOI: 10.3389/fimmu.2023.1070076.
A New Treatment Landscape for RCC: Association of the Human Microbiome with Improved Outcomes in RCC.
Piao X, Byun Y, Zheng C, Song S, Kang H, Kim W
Cancers (Basel). 2023; 15(3).
PMID: 36765892
PMC: 9913391.
DOI: 10.3390/cancers15030935.
The emerging potential of microbiome transplantation on human health interventions.
Junca H, Pieper D, Medina E
Comput Struct Biotechnol J. 2022; 20:615-627.
PMID: 35140882
PMC: 8801967.
DOI: 10.1016/j.csbj.2022.01.009.
The clinical impact of concomitant medication use on the outcome of postoperative recurrent non-small-cell lung cancer in patients receiving immune checkpoint inhibitors.
Takada K, Shimokawa M, Takamori S, Shimamatsu S, Hirai F, Ono Y
PLoS One. 2022; 17(2):e0263247.
PMID: 35130287
PMC: 8820612.
DOI: 10.1371/journal.pone.0263247.
Hepatocellular Carcinoma Immunotherapy and the Potential Influence of Gut Microbiome.
Temraz S, Nassar F, Kreidieh F, Mukherji D, Shamseddine A, Nasr R
Int J Mol Sci. 2021; 22(15).
PMID: 34360566
PMC: 8346024.
DOI: 10.3390/ijms22157800.
Antibiotic use influences outcomes in advanced pancreatic adenocarcinoma patients.
Mohindroo C, Hasanov M, Rogers J, Dong W, Prakash L, Baydogan S
Cancer Med. 2021; 10(15):5041-5050.
PMID: 34250759
PMC: 8335807.
DOI: 10.1002/cam4.3870.
A new biological triangle in cancer: intestinal microbiota, immune checkpoint inhibitors and antibiotics.
Zhang J, Dai Z, Yan C, Zhang W, Wang D, Tang D
Clin Transl Oncol. 2021; 23(12):2415-2430.
PMID: 34125407
PMC: 8557192.
DOI: 10.1007/s12094-021-02659-w.
Relating Gut Microbiome and Its Modulating Factors to Immunotherapy in Solid Tumors: A Systematic Review.
Huang C, Li M, Liu B, Zhu H, Dai Q, Fan X
Front Oncol. 2021; 11:642110.
PMID: 33816289
PMC: 8012896.
DOI: 10.3389/fonc.2021.642110.
Oral administration of promotes antitumor efficacy via dendritic cells-derived interleukin 12.
Li Q, Li Y, Wang Y, Xu L, Guo Y, Wang Y
Oncoimmunology. 2021; 10(1):1868122.
PMID: 33537172
PMC: 7833736.
DOI: 10.1080/2162402X.2020.1868122.
Gut microbiota: impacts on gastrointestinal cancer immunotherapy.
Lau H, Jao-Yiu Sung J, Yu J
Gut Microbes. 2021; 13(1):1-21.
PMID: 33435800
PMC: 7808428.
DOI: 10.1080/19490976.2020.1869504.
Infections and Immunotherapy in Lung Cancer: A Bad Relationship?.
Belluomini L, Caldart A, Avancini A, Dodi A, Trestini I, Kadrija D
Int J Mol Sci. 2020; 22(1).
PMID: 33375194
PMC: 7793072.
DOI: 10.3390/ijms22010042.
Is the survival of patients treated with ipilimumab affected by antibiotics? An analysis of 1585 patients from the French National hospital discharge summary database (PMSI).
Cren P, Bertrand N, Le Deley M, Genin M, Mortier L, Odou P
Oncoimmunology. 2020; 9(1):1846914.
PMID: 33299658
PMC: 7714497.
DOI: 10.1080/2162402X.2020.1846914.
Comparative analysis of antibiotic exposure association with clinical outcomes of chemotherapy versus immunotherapy across three tumour types.
Kulkarni A, Ebadi M, Zhang S, Meybodi M, Ali A, DeFor T
ESMO Open. 2020; 5(5):e000803.
PMID: 32900789
PMC: 7477978.
DOI: 10.1136/esmoopen-2020-000803.
